The Chemours Company (NYSE:CC) Shares Acquired by Inspire Investing LLC

Inspire Investing LLC increased its stake in The Chemours Company (NYSE:CC) by 17.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,799 shares of the specialty chemicals company’s stock after acquiring an additional 3,523 shares during the period. Inspire Investing LLC’s holdings in Chemours were worth $402,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CC. FMR LLC raised its position in Chemours by 3.5% in the 3rd quarter. FMR LLC now owns 18,142,202 shares of the specialty chemicals company’s stock valued at $368,650,000 after purchasing an additional 618,361 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Chemours by 1.2% during the third quarter. Geode Capital Management LLC now owns 2,491,748 shares of the specialty chemicals company’s stock worth $50,646,000 after buying an additional 28,803 shares during the period. Appian Way Asset Management LP purchased a new position in Chemours in the third quarter worth approximately $34,151,000. Vision One Management Partners LP acquired a new position in Chemours during the 3rd quarter worth approximately $28,252,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Chemours by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,229,052 shares of the specialty chemicals company’s stock valued at $24,974,000 after purchasing an additional 32,590 shares during the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CC has been the subject of a number of analyst reports. Morgan Stanley lowered their target price on shares of Chemours from $25.00 to $22.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Barclays upped their price objective on Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Mizuho cut their target price on Chemours from $22.00 to $21.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. The Goldman Sachs Group lowered their price target on Chemours from $24.00 to $21.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $25.00 price objective on shares of Chemours in a report on Thursday, December 12th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Chemours currently has an average rating of “Hold” and a consensus price target of $23.75.

Insider Buying and Selling

In related news, SVP Alvenia Scarborough sold 7,500 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the transaction, the senior vice president now owns 16,645 shares of the company’s stock, valued at $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.47% of the stock is currently owned by corporate insiders.

Chemours Trading Down 1.6 %

Shares of CC stock opened at $19.68 on Friday. The company has a market capitalization of $2.94 billion, a P/E ratio of 39.35 and a beta of 1.83. The company has a current ratio of 1.73, a quick ratio of 0.92 and a debt-to-equity ratio of 6.05. The business’s 50 day moving average is $19.18 and its two-hundred day moving average is $19.65. The Chemours Company has a twelve month low of $15.10 and a twelve month high of $32.25.

Chemours (NYSE:CC) last announced its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The company had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.44 billion. During the same period in the previous year, the company posted $0.64 EPS. Chemours’s revenue was up .9% compared to the same quarter last year. Equities analysts forecast that The Chemours Company will post 1.19 EPS for the current year.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.